Pharmaceutical lawyers from the Texas lawfirm Watts Guerra smell blood and have targeted the Danish diabetes group Novo Nordisk. On its webpage the firm invites Victoza-users to contact them to be included in a class action against the Danish company.
Watts Guerra has targeted Novo’s Victoza because of an escalating debate about the risks of pancreatitis and pancreatic cancer from the popular diabetes drugs known as GLP-1 analogues, to which Victoza belongs.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app